CAMBRIDGE, Massachusetts, USA – June 8, 2026
MetaVia Inc. has unveiled new late-breaking clinical and preclinical data at the American Diabetes Association (ADA) 2026 Scientific Sessions, highlighting the growing potential of its cardiometabolic disease pipeline led by DA-1726 and vanoglipel (DA-1241). The findings demonstrate encouraging progress in obesity, type 2 diabetes (T2D), and metabolic dysfunction-associated steatohepatitis (MASH), positioning MetaVia as an emerging innovator in one of the pharmaceutical industry’s most competitive therapeutic areas. The data presented at ADA 2026 showed significant weight reduction, favorable safety outcomes, and promising combination-treatment strategies that could address multiple metabolic disorders simultaneously. These latest results strengthen confidence in MetaVia’s clinical development strategy and support continued advancement of both programs toward later-stage development.
DA-1726 Demonstrates Strong Weight-Loss Potential in Phase 1 Study
The headline clinical data focused on DA-1726, MetaVia’s investigational dual agonist targeting both GLP-1 receptors (GLP1R) and glucagon receptors (GCGR). In a Phase 1 multiple ascending dose study involving obese adults, the higher 48 mg cohort achieved up to 9.1% mean body weight reduction by Day 54, with no evidence of a weight-loss plateau. The investigational therapy also produced substantial improvements in waist circumference and body mass index, reinforcing its potential as a differentiated obesity treatment. Patients receiving DA-1726 experienced a 6.1% reduction in body weight by Day 26, which continued to improve throughout the study period.
Waist circumference decreased by 9.8 centimeters, while body mass index showed meaningful reductions consistent with the observed weight-loss profile. Importantly, DA-1726 demonstrated favorable safety and tolerability, with predominantly mild-to-moderate gastrointestinal adverse events and no treatment-related serious adverse events or discontinuations reported. These findings suggest that the once-weekly therapy could offer a compelling alternative in the rapidly expanding obesity market, where demand for highly effective weight-management medicines continues to accelerate.
Vanoglipel Combination Data Highlights Opportunities in MASH and Diabetes
Advertisement
MetaVia also presented promising preclinical evidence supporting vanoglipel, a novel GPR119 agonist being developed for both MASH and type 2 diabetes. In a diet-induced obese mouse model of MASH, combining vanoglipel with resmetirom generated synergistic hepatoprotective and weight-loss benefits. The combination achieved a 23.6% reduction in body weight, significantly reduced liver fat accumulation, improved fibrosis-related biomarkers, and delivered the largest reduction in liver injury markers among all treatment groups. Researchers noted that this represents the first demonstration of the therapeutic potential achieved through combined targeting of GPR119 and thyroid hormone receptor beta (THRβ) pathways in MASH.
Additional studies evaluating vanoglipel alongside metformin demonstrated superior metabolic outcomes compared with either treatment alone. Combination therapy reduced fasting and non-fasting glucose levels while delivering a 16.3% reduction in body weight, significantly outperforming monotherapy approaches. Researchers also observed improvements in gut hormone activity, including elevated GLP-1 and peptide YY levels, suggesting enhanced metabolic regulation and appetite control. These findings support vanoglipel’s potential role as a versatile combination therapy capable of complementing existing standards of care across multiple metabolic diseases.
Expanding Opportunities in Cardiometabolic Disease Treatment
The ADA 2026 presentations underscore MetaVia’s ambition to address some of the largest unmet needs in metabolic medicine. With obesity, MASH, and type 2 diabetes affecting hundreds of millions of people globally, the company’s dual strategy of advancing innovative monotherapies while exploring combination-treatment opportunities could create significant clinical and commercial value.
Company leadership emphasized that the data further validates DA-1726 as a differentiated obesity therapy and highlights vanoglipel’s potential as a metabolic backbone for combination approaches. As the race to develop next-generation cardiometabolic therapies intensifies, MetaVia’s latest findings provide encouraging evidence that its pipeline could contribute meaningfully to future treatment options for patients living with chronic metabolic diseases.
Source: MetaVia press release
